Four Biotechs Hit US IPO Market as Sector Prospects Brighten

Signs of a resurgence in the biotechnology sector picked up late last year as shares of drug developers started to climb. With a quartet of initial public offerings this week, hopes are even higher.

Hair-restoration specialist Veradermics Inc.’s Wednesday debut is first of the four companies listing this week, which together could raise more than $900 million from investors. The ample activity is the latest sign that investor enthusiasm for cutting-edge biotechs is on the upswing.

“The broader biotech sector has rallied back to levels we haven’t seen since 2021,” said Jack Bannister, senior managing director in equity ...